Jump to the top of the page

Showing 620 – 630 of 1303 results

  • Silence Therapeutics plc

    William Blair & Company initiated research coverage of Silence Therapeutics plc (SLN $15.50), a clinical-stage biopharmaceutical company focused on developing proprietary GalNAc-conjugated siRNA therapeutics for genetically defined life-threatening disorders.

  • Cloudflare Inc Initiation

    William Blair & Company initiated research coverage of Cloudflare, Inc. (NET $36.12). The company provides a broad range of network services over its global cloud platform that enhance the security, performance, and reliability of business-critical applications while eliminating the cost and complexity of managing and integrating individual network hardware.

  • Trean Insurance Group Inc Initiation

    William Blair & Company initiated research coverage of Trean Insurance Group, Inc. (TIG $16.70), which provides products and services to specialty insurance markets.

  • Bridging Generation Gaps Featured in Latest Courageous Conversations

    Communications expert Scott Zimmer shared humorous stories from his childhood during William Blair’s latest Courageous Conversations event that illustrated how each generation brings a different perspective to work based on experiences from their teen years.

  • Rock 'n' Roll Inspires Philanthropy

    William Blair client Dr. Jeff Heddles shares his journey as a focal donor to help find a cure for a rare childhood disease.

  • Small Acts Build Thriving Workplaces

    It is the small acts of courage employees demonstrate every day that can help build inclusive workplaces and thriving businesses, entrepreneur and CEO of Bonfire Suzanne Muchin told colleagues during William Blair’s most recent Courageous Conversations event.

  • Neighborhood Entrepreneurship Lab Empowering Small Local Businesses

    Discover the ways William Blair client Bob Crawford Jr. is helping business owners unlock capital, coaching, and connections to strengthen Chicago communities.

  • Third-Quarter Update on Biotech Funding, Pipeline Growth, and R&D Spending

    Equity analysts Max Smock and Matt Larew examine the biotech industry’s funding levels, product pipeline, and pace of spending on research and development.

  • Edward J. Dunphy

    View biography for Edward J. Dunphy, Partner, Wealth Advisor.

  • Hugo Scott-Gall

    View the biography for Hugo Scott-Gall, partner, head of the global equity team, and portfolio manager.

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures